Immersive Virtual Reality in Neuropalliative Care: A Pilot Study in ALS Outpatients

Immersive Virtual Reality in Neuropalliative Care: A Pilot Study in ALS Outpatients - ViEW_ALS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00039873

Enrollment

Registered

2026-04-15

Start date

2023-09-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G12.2

Interventions

Group 1: VR interventions in patients with ALS (3 sessions of 15–30 minutes each within 1 week). Group 2: Active control group: 2D interventions in patients with ALS (3 sessions of 15–30 minutes each

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - ALS diagnosed according to the Gold Coast criteria - living in Berlin - relevant non-motor symptom burden (ESAS = 4) - sufficient language proficiency (minimum B2 level)

Exclusion criteria

Exclusion criteria: - Cognitive impairment relevant to study participation and questionnaire completion - Functionally relevant visual impairment: visual field < 50%, non-correctable diplopia - Non-compensable vestibular dysfunction - Quantitative or qualitative disturbance of consciousness - Open head wounds or injuries to the shoulder girdle or upper extremities - Treatment-refractory epilepsy - Non-compensable hearing impairment - Inability to securely fit the headset on the patient’s head - Acute pain conditions

Design outcomes

Primary

Measure	Time frame
Changes in symptom burden following VR and 2D interventions, assessed using the Edmonton Symptom Assessment System (ESAS), measured before and 10 minutes after each intervention, as well as one week after the final intervention.	—

Secondary

Measure	Time frame
1) Assessment of feasibility and acceptance based on consent rate, drop-out rate, and semi-structured interviews after each intervention. 2) Degree of perceived immersion of the interventions measured using the IGroup Presence Questionnaire (IPQ) after the first intervention. 3) Assessment of potential side effects of the interventions using the Simulator Sickness Questionnaire (SSQ) before and 10 minutes after each intervention.	—

Measure

Time frame

1) Assessment of feasibility and acceptance based on consent rate, drop-out rate, and semi-structured interviews after each intervention. 2) Degree of perceived immersion of the interventions measured using the IGroup Presence Questionnaire (IPQ) after the first intervention. 3) Assessment of potential side effects of the interventions using the Simulator Sickness Questionnaire (SSQ) before and 10 minutes after each intervention.

—

Countries

Germany

Contacts

Public ContactSarah Herwest

Klinik für Neurologie mit experimenteller Neurologie, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum

sarah.herwest@charite.de+4930450560022

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026